Bristol-Myers Squibb Company Reports Completion of Public Debt Offering
Summary
On November 10, 2025, BMS Ireland Capital Funding Designated Activity Company, a wholly-owned subsidiary of Bristol-Myers Squibb Company, completed a public offering of five series of Euro-denominated Notes (via Ex. 5.1). These Notes, maturing between 2030 and 2055 with interest rates from 2.973% to 4.581%, are fully and unconditionally guaranteed by Bristol-Myers Squibb Company. The Company plans to use the net proceeds from this offering, combined with approximately $3.0 billion of cash on hand, to fund the...
Why It Matters
This significant multi-billion Euro debt offering provides substantial capital for Bristol-Myers Squibb Company, intended to fund future initiatives. This financing event impacts the company's capital structure and liquidity.
These filing summaries are free and always will be. If this helped you spot material events, consider supporting us.
Want to see how BMY traded around this filing?
Check real-time charts and technical analysis on TradingView to see market reaction to this event.
View BMY Charts on TradingViewAffiliate link
Key Quote
“The Company intends to use the net proceeds of the Offering, together with approximately $3.0 billion of cash on hand, (i) to fund the.”
— From Item 8.01
Filing Details
Reported Items
Additional Information
- CIK Number
- 0000014272
- Filing Date
- Monday, November 10, 2025
- Filing Time
- 12:00 AM UTC
- Form Type
- 8-K
- Materiality Level
- high
- Sentiment
- neutral